Research supported and driven by the Countdown to a Cure initiative will be guided by a group of eminent scientists who make up the Cure Council.
David Baltimore, Ph.D.
Professor of Biology, California Institute of Technology
In 1975, at the age of 37, Dr. Baltimore shared the Nobel Prize for Physiology or Medicine with Howard Temin and Renato Dulbecco. The citation reads, "for their discoveries concerning the interaction between tumor viruses and the genetic material of the cell." At the time, Dr. Baltimore's greatest contribution to virology was his discovery of reverse transcriptase, which is essential for the reproduction of retroviruses such as HIV.
Françoise Barré-Sinoussi, Ph.D.
Director of the Regulation of Retroviral Infections Division (Unité de Régulation des Infections Rétrovirales), Institut Pasteur, Paris, France
In 2008, Dr. Barré-Sinoussi was awarded the Nobel Prize in Physiology or Medicine, together with her former mentor, Luc Montagnier, for their discovery of HIV. She served as president of the International AIDS Society from 2012 to 2014 and is chair of the Towards an HIV Cure project, an initiative of the International AIDS Society.
Myron (Mike) Cohen, M.D.
Associate Vice Chancellor for Global Health; J. Herbert Bate Distinguished Professor of Medicine, Microbiology and Immunology, and Public Health; Director, Institute for Global Health and Infectious Diseases; Chief, Division of Infectious Diseases; Director, Center for Infectious Diseases at University of North Carolina
The author of more than 500 publications, Dr. Cohen has written extensively about the prevention of HIV infection. The HIV Prevention Trials Network 052 study (HPTN 052), led by Dr. Cohen, was named the 2011 Breakthrough of the Year by the journal Science. The study demonstrated that treating HIV-positive people early can lead to a 96% reduction in HIV transmission to their sex partners.
Beatrice Hahn, M.D.
Professor of Medicine, Perelman School of Medicine, University of Pennsylvania
In 2002, Discover magazine named Dr. Hahn one of “The 50 Most Important Women in Science.” Her laboratory has had a longstanding interest in elucidating the origins and evolution of human and simian immunodeficiency viruses, and in studying HIV/SIV gene function and disease mechanisms from an evolutionary perspective. She is recognized for deciphering the primate origins of human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2).
Basic Science, Vaccines, and Cure Project Coordinator at Treatment Action Group (TAG)
A highly respected voice in AIDS research, Richard Jefferys has more than 20 years experience in the field of HIV treatment access, clinical trials, and vaccine and cure research. Since joining the Treatment Action Group in late 2001, Richard has worked for TAG’s Michael Palm Basic Science, Vaccines, and Cure Project. He also writes on the pathogenesis and immunology of HIV infection for a range of publications.
Carl June, M.D.
Professor in Immunology, Perelman School of Medicine, University of Pennsylvania
Dr. June’s pioneering research involves immunotherapy for cancer, chronic infections and HIV. Using gene therapy and stem cell transplantation in cancer, specifically chronic lymphocytic leukemia and acute lymphoblastic leukemia, Dr. June has treated cancers that were previously unresponsive to treatment. In September 2011, The New York Times described his work as “a turning point in the long struggle to develop effective gene therapies against cancer.”